Literature DB >> 10674041

Association of HLA-DRB1 alleles with giant cell tumour of bone.

S S Varanasi1, N A Athanasou, I Briceno, S S Papiha, H K Datta.   

Abstract

AIM: To examine the possible influence of the MHC class II antigens alleles in the formation of the multinucleate aggressive giant cell tumour of bone.
METHODS: HLA class II antigen alleles were investigated in eight white patients from north east England with confirmed diagnosis of giant cell tumour of bone. All had locally aggressive, immunophenotypically HLA-DR negative giant cell tumours.
RESULTS: Five of the eight patients were found to be positive for HLA-DRB1*0801/3, the distribution of this allele in healthy white controls being quite low (2%). All but one of the patients possessing DRB1*080 also expressed DRB1*070.
CONCLUSIONS: HLA-DRB1*080 is pre-dominant in patients with immunophenotypic HLA-DR negative giant cell tumour of bone; individuals with the genotype 070/080 are at particularly high risk of developing giant cell tumour of bone.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10674041      PMCID: PMC501578          DOI: 10.1136/jcp.52.10.782

Source DB:  PubMed          Journal:  J Clin Pathol        ISSN: 0021-9746            Impact factor:   3.411


  10 in total

1.  Phenotypic characterisation of mononuclear and multinucleated cells of giant cell tumour of bone.

Authors:  C J Joyner; J M Quinn; J T Triffitt; M E Owen; N A Athanasou
Journal:  Bone Miner       Date:  1992-01

Review 2.  Modulation of osteoclast differentiation.

Authors:  T Suda; N Takahashi; T J Martin
Journal:  Endocr Rev       Date:  1992-02       Impact factor: 19.871

3.  PCR-SSO typing for HLA-DRB alleles.

Authors:  R W Vaughan
Journal:  Eur J Immunogenet       Date:  1991 Feb-Apr

4.  Immunophenotype of multinucleated and mononuclear cells in giant cell lesions of bone and soft tissue.

Authors:  I A Doussis; B Puddle; N A Athanasou
Journal:  J Clin Pathol       Date:  1992-05       Impact factor: 3.411

5.  Giant-cell tumour of bone: an analysis of fifty-two cases.

Authors:  P J McGrath
Journal:  J Bone Joint Surg Br       Date:  1972-05

6.  Tendon lesions and soft tissue rheumatism--great outback or great opportunity?

Authors:  T E Cawston; G P Riley; B L Hazleman
Journal:  Ann Rheum Dis       Date:  1996-01       Impact factor: 19.103

7.  Characterization of a subtype of primary osteoclastoma: extracellular calcium but not calcitonin inhibits aggressive HLA-DR-positive osteoclastoma possessing 'functional' calcitonin receptors.

Authors:  H Rathod; A J Malcolm; J I Gillespie; V Berry; J Pooley; N H Piggott; H K Datta
Journal:  J Pathol       Date:  1994-12       Impact factor: 7.996

8.  The human osteoclast precursor circulates in the monocyte fraction.

Authors:  Y Fujikawa; J M Quinn; A Sabokbar; J O McGee; N A Athanasou
Journal:  Endocrinology       Date:  1996-09       Impact factor: 4.736

9.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

Authors:  H Yasuda; N Shima; N Nakagawa; K Yamaguchi; M Kinosaki; S Mochizuki; A Tomoyasu; K Yano; M Goto; A Murakami; E Tsuda; T Morinaga; K Higashio; N Udagawa; N Takahashi; T Suda
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-31       Impact factor: 11.205

10.  HLA DQA, DQB, and DRB genotyping by oligonucleotide analysis: distribution of alleles and haplotypes in British caucasoids.

Authors:  D G Doherty; R W Vaughan; P T Donaldson; A P Mowat
Journal:  Hum Immunol       Date:  1992-05       Impact factor: 2.850

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.